Measuring Tumor Acidosis with PET/MRI Contrast Agents
使用 PET/MRI 造影剂测量肿瘤酸中毒
基本信息
- 批准号:9750458
- 负责人:
- 金额:$ 24万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-03-01 至 2020-12-31
- 项目状态:已结题
- 来源:
- 关键词:4-nitrophenolAcidosisAddressAnimalsAttentionBenchmarkingBicarbonatesBiological MarkersBladderChelating AgentsClinicalConcentration measurementContrast MediaCyclotronsDataDetectionDevelopmentDiagnosisDrug KineticsEnsureEnvironmentEvaluationGadoliniumGoalsImmunotherapyInductively Coupled Plasma Mass SpectrometryInfrastructureInjectionsIonsKidneyLabelLeadLigandsMRI ScansMagnetic Resonance ImagingMalignant neoplasm of pancreasMapsMeasurementMeasuresMicroelectrodesModelingMusNitrophenolPatientsPharmacotherapyPositron-Emission TomographyProblem SolvingProtocols documentationRadioactivityRadiochemistryRadiolabeledReceptor CellRelaxationReportingResearchResearch PersonnelScanningSmall Animal Imaging SystemsSolid NeoplasmSystemTechnologyTissuesTracerTumor Tissueanimal imagingbasecancer imagingcellular imagingclinical translationcontrast imagingdesignexperienceextracellularhuman cancer mouse modelimaging modalityimaging studyimprovedin vivoinnovationmetabolic abnormality assessmentmetaiodobenzylguanidinemetal chelatormolecular imagingnon-invasive imagingpre-clinicalpredicting responseresponsesuccesstumortumor microenvironment
项目摘要
Our goal is to quantitatively measure extracellular pH (pHe) in the tumor microenvironment to assess tumor
acidosis. These assessments can be used to improve evaluations of solid tumors, to aid in predicting the
response to immunotherapy before the treatment is initiated, and to evaluate the early response of tumors to
many types of drug treatment. These multiple applications can provide strong impact for studies of mouse tumor
models, and eventually for patients who have solid tumors.
To meet this goal, we propose to develop PET/MRI contrast agents that can quantitatively measure pHe,
and apply these agents during simultaneous PET/MRI studies in mouse models of human cancers. Dynamic
changes in the relaxation-based MR image contrast are sensitive to tumor pHe as well as the concentration of
the agent in tumor tissue, while the PET image can be used to measure the concentration of the agent in the
tumor. Therefore, the PET results can be used to account for the effect of concentration on MR image contrast,
which can improve the quantitative measurement of tumor pHe. To overcome the difference in detection
sensitivities of PET and MRI, we will co-inject 0.01% “hot” radiolabeled agent and 99.99% “cold” MRI contrast
agent. Notably, this approach would fail to image cell receptors or intracellular biomarkers, but is ideally suited
to interrogate the extracellular tumor microenvironment. In particular, these agents are designed to have the
same pharmacokinetic delivery to the extracellular tumor microenvironment during the first 10 minutes after co-
injection, so that the MBq radioactivity measurement with PET can be used to evaluate the M concentration of
the MRI contrast agent. Therefore, our development of contrast agents for simultaneous PET/MRI has strong
innovation for cancer imaging.
Accurate and precise measurements of tumor pHe requires great attention to rigor, especially to address potential
inaccuracies and imprecisions with both imaging modalities. Therefore, we have designed a strong research
approach with careful attention to rigor. We have assembled a team of strong investigators who have extensive
experience in developing “smart” MRI contrast agents and PET tracers, and performing molecular imaging studies
with small animal tumor models especially for imaging tumor acidosis. We have recently obtained one of the few
commercial PET/MRI systems for small animal imaging world-wide, and MD Anderson has an extensive infrastructure
for radiochemistry and small animal imaging, which attests to our strong environment.
Our deliverable is a fundamentally new class of contrast agents for molecular imaging with PET/MRI. As a
longer term goal, our PET/MRI contrast agents have outstanding potential for clinical translation, which will
provide a transformative “game changing technology” for clinical PET/MRI.
我们的目标是定量测量肿瘤微环境中的细胞外pH值(pHe),以评估肿瘤微环境中的pH值。
酸中毒这些评估可用于改善实体瘤的评估,以帮助预测肿瘤的预后。
在治疗开始之前,评估肿瘤对免疫疗法的早期反应,
多种药物治疗。这些多重应用可以为小鼠肿瘤的研究提供强大的影响
模型,并最终用于患有实体瘤的患者。
为了实现这一目标,我们建议开发能够定量测量pHe的PET/MRI造影剂,
并在人类癌症小鼠模型的同步PET/MRI研究中应用这些药物。动态
基于弛豫的MR图像对比度的变化对肿瘤pHe以及
肿瘤组织中的药剂,而PET图像可用于测量肿瘤组织中药剂的浓度。
肿瘤因此,PET结果可用于解释浓度对MR图像对比度的影响,
其可改善肿瘤pHe的定量测量。为了克服检测上的差异
为了提高PET和MRI的灵敏度,我们将共同注射0.01%“热”放射性标记剂和99.99%“冷”MRI造影剂
剂值得注意的是,这种方法无法成像细胞受体或细胞内生物标志物,但非常适合
来研究肿瘤细胞外的微环境。特别地,这些代理被设计为具有
在共同给药后的前10分钟期间,向细胞外肿瘤微环境的药代动力学递送相同。
因此,使用PET进行的MBq放射性测量可用于评估
MRI造影剂。因此,我们开发的同步PET/MRI造影剂具有很强的
癌症成像的创新。
肿瘤pHe的准确和精确测量需要高度重视严谨性,特别是要解决潜在的
两种成像模式的不准确性和不精确性。因此,我们设计了一个强大的研究
仔细注意严谨的方法。我们已经组建了一个强大的调查小组,
在开发“智能”MRI造影剂和PET示踪剂以及进行分子成像研究方面的经验
与小动物肿瘤模型,特别是用于成像肿瘤酸中毒。我们最近获得了为数不多的
MD安德森拥有广泛的基础设施,
用于放射化学和小动物成像,这证明了我们强大的环境。
我们的产品是一种全新的PET/MRI分子成像造影剂。作为
长期目标是,我们的PET/MRI造影剂具有出色的临床转化潜力,
为临床PET/MRI提供一种变革性的“改变游戏规则的技术”。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Mark David Pagel其他文献
Mark David Pagel的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Mark David Pagel', 18)}}的其他基金
Exploiting Melanin Synthesis to Improve Tumor Detection with Multispectral Optoacoustic Tomography and Optical Guided Surgery
利用多光谱光声断层扫描和光引导手术利用黑色素合成来改善肿瘤检测
- 批准号:
9978211 - 财政年份:2020
- 资助金额:
$ 24万 - 项目类别:
Exploiting Melanin Synthesis to Improve Tumor Detection with Multispectral Optoacoustic Tomography and Optical Guided Surgery
利用多光谱光声断层扫描和光引导手术利用黑色素合成来改善肿瘤检测
- 批准号:
10152589 - 财政年份:2020
- 资助金额:
$ 24万 - 项目类别:
Early phase clinical trial for imaging tumor acidosis in breast cancer patients using acidoCEST MRI
使用 AcidoCEST MRI 对乳腺癌患者肿瘤酸中毒进行成像的早期临床试验
- 批准号:
8948796 - 财政年份:2015
- 资助金额:
$ 24万 - 项目类别:
Detection of in vivo enzyme activities with CEST MRI
使用 CEST MRI 检测体内酶活性
- 批准号:
8495297 - 财政年份:2012
- 资助金额:
$ 24万 - 项目类别:
Measuring extracellular pH in pre-clinical tumor models with CEST MRI
使用 CEST MRI 测量临床前肿瘤模型中的细胞外 pH 值
- 批准号:
8446309 - 财政年份:2012
- 资助金额:
$ 24万 - 项目类别:
Detection of in vivo enzyme activities with CEST MRI
使用 CEST MRI 检测体内酶活性
- 批准号:
8852091 - 财政年份:2012
- 资助金额:
$ 24万 - 项目类别:
Measuring extracellular pH in pre-clinical tumor models with CEST MRI
使用 CEST MRI 测量临床前肿瘤模型中的细胞外 pH 值
- 批准号:
8286741 - 财政年份:2012
- 资助金额:
$ 24万 - 项目类别:
Measuring extracellular pH in pre-clinical tumor models with CEST MRI
使用 CEST MRI 测量临床前肿瘤模型中的细胞外 pH 值
- 批准号:
8817152 - 财政年份:2012
- 资助金额:
$ 24万 - 项目类别:
Detection of in vivo enzyme activities with CEST MRI
使用 CEST MRI 检测体内酶活性
- 批准号:
8353415 - 财政年份:2012
- 资助金额:
$ 24万 - 项目类别:
Detection of in vivo protease activities using PARACEST MRI contrast agents
使用 PARACEST MRI 造影剂检测体内蛋白酶活性
- 批准号:
7451742 - 财政年份:2008
- 资助金额:
$ 24万 - 项目类别:
相似国自然基金
肿瘤微环境因子Lactic acidosis在肿瘤细胞耐受葡萄糖剥夺中的作用机制研究
- 批准号:81301707
- 批准年份:2013
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Identification of factor to induce lactic acidosis in pre-metastatic niche
转移前微环境中诱导乳酸性酸中毒的因素的鉴定
- 批准号:
23K06620 - 财政年份:2023
- 资助金额:
$ 24万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Carbonic Anhydrase IX Acts as a Novel CO2/HCO3- Sensor and Protects the Pulmonary Endothelial Barrier from Acidosis
碳酸酐酶 IX 作为新型 CO2/HCO3- 传感器并保护肺内皮屏障免受酸中毒的影响
- 批准号:
10678442 - 财政年份:2023
- 资助金额:
$ 24万 - 项目类别:
Investigation based on both basic and clinical study about acidosis caused by piganide, SGLT2 inhibitor and surgical stress
皮甘尼、SGLT2抑制剂和手术应激引起的酸中毒的基础和临床研究
- 批准号:
23K08372 - 财政年份:2023
- 资助金额:
$ 24万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Role of proton-sensing G-protein-coupled receptors in the regulation of microglia and microvessel endothelial cell function in brain acidosis in a mouse ischemia reperfusion model.
质子感应 G 蛋白偶联受体在小鼠缺血再灌注模型脑酸中毒中调节小胶质细胞和微血管内皮细胞功能的作用。
- 批准号:
22K07342 - 财政年份:2022
- 资助金额:
$ 24万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Magnetic Resonance Fingerprinting of Tumor Vascular Perfusion and Acidosis
肿瘤血管灌注和酸中毒的磁共振指纹图谱
- 批准号:
10593285 - 财政年份:2022
- 资助金额:
$ 24万 - 项目类别:
Acidosis in pulmonary endothelial injury and repair
酸中毒与肺内皮损伤与修复
- 批准号:
10341493 - 财政年份:2022
- 资助金额:
$ 24万 - 项目类别:
Acidosis in pulmonary endothelial injury and repair
酸中毒与肺内皮损伤与修复
- 批准号:
10558528 - 财政年份:2022
- 资助金额:
$ 24万 - 项目类别:
Characterization of an abundant lactate-utilizing Campylobacter involved in mitigating rumen acidosis
参与减轻瘤胃酸中毒的丰富乳酸利用弯曲杆菌的表征
- 批准号:
557929-2021 - 财政年份:2022
- 资助金额:
$ 24万 - 项目类别:
Postgraduate Scholarships - Doctoral
Impact of metabolic acidosis on muscle mitochondrial energetics, metabolic health and physical endurance in persons with chronic kidney disease
代谢性酸中毒对慢性肾病患者肌肉线粒体能量学、代谢健康和身体耐力的影响
- 批准号:
10278747 - 财政年份:2021
- 资助金额:
$ 24万 - 项目类别:
Impact of metabolic acidosis on muscle mitochondrial energetics, metabolic health and physical endurance in persons with chronic kidney disease
代谢性酸中毒对慢性肾病患者肌肉线粒体能量学、代谢健康和身体耐力的影响
- 批准号:
10671682 - 财政年份:2021
- 资助金额:
$ 24万 - 项目类别: